Titre
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Wiedemann, A.
Auteure/Auteur
Pellaton, C.
Auteure/Auteur
Dekeyser, M.
Auteure/Auteur
Guillaumat, L.
Auteure/Auteur
Déchenaud, M.
Auteure/Auteur
Krief, C.
Auteure/Auteur
Lacabaratz, C.
Auteure/Auteur
Grimbert, P.
Auteure/Auteur
Pantaleo, G.
Auteure/Auteur
Lévy, Y.
Auteure/Auteur
Durrbach, A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2296-858X
Statut éditorial
Publié
Date de publication
2022
Volume
9
Première page
978764
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR-31 receiving CNI and 21 receiving belatacept-were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens.
PID Serval
serval:BIB_3A74857F7FD8
PMID
Open Access
Oui
Date de création
2022-09-20T12:45:56.618Z
Date de création dans IRIS
2025-05-20T16:28:57Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
36072955_BIB_3A74857F7FD8.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
634.61 KB
Format
Adobe PDF
PID Serval
serval:BIB_3A74857F7FD8.P001
URN
urn:nbn:ch:serval-BIB_3A74857F7FD83
Somme de contrôle
(MD5):9128e593f7c5820d0d85744cd49f1e5f